Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
VistaGen Therapeutics is a biotechnology business based in the US. VistaGen Therapeutics stocks (VTGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.77 – the same closing value as a week prior. VistaGen Therapeutics employs 32 staff and has a market cap (total outstanding stock value) of $28.9 million.
Promoted
National Bank Direct Brokerage
Finder Award
Interactive Brokers
| Latest market close | $0.13 |
|---|---|
| 52-week range | $0.08 - $1.22 |
| 50-day moving average | $0.14 |
| 200-day moving average | $0.15 |
| Wall St. target price | $0.20 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.32 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $0.13 from 2023-05-26
| 1 week (2023-05-24) | 0.13 |
|---|---|
| 1 month (2023-05-01) | -7.14% |
| 3 months (2023-03-03) | -23.39% |
| 6 months (2022-12-01) | -4.41% |
| 1 year (2022-05-27) | N/A |
|---|---|
| 2 years (2021-05-28) | -94.98% |
| 3 years (2020-05-29) | 0.4416 |
| 5 years (2018-05-31) | 1.41 |
| Operating margin TTM | 17506.02% |
|---|---|
| Gross profit TTM | $1.1 million |
| Return on assets TTM | -66.24% |
| Return on equity TTM | -126.59% |
| Profit margin | 0% |
| Book value | $0.10 |
| Market capitalisation | $28.9 million |
TTM: trailing 12 months
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
VistaGen Therapeutics's shares were split on a 1:20 basis on 14 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.08 up to $1.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 1.0014. This would suggest that VistaGen Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license agreement with Pherin Pharmaceuticals, Inc.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Your guide to bad credit car loans in BC and how to find the right financing for your needs.
